Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.

Hum Vaccin Immunother · 2021 · PMC8189101 · PMID 33667140

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

115 , 116 While the primary analysis of the phase II/III trial with naptumomab estafenatox was negative for improved survival versus the IFN-γ control arm, the patient subgroup having below median of baseline anti-SEA/E-120 showed a trend toward improved OS and PFS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.